MDM2 and neoplasm: In 2018, Wang’s team designed and synthesized PROTAC molecules using the MDM2 inhibitor MI-1061, which not only exhibited significant degradation of leukocytes but also markedly inhibited tumor growth in a mouse model.506 Subsequently, Tang’s team developed WB156 (212), a highly efficient MDM2-PROTAC comprising a nutlin derivative linked to the CRBN ligand lenalidomide (Table 4).